Influence of leukotrienes on in vitro growth of human mammary carcinoma cell line MCF-7

被引:12
|
作者
Przylipiak, A
Hafner, J
Przylipiak, J
Runnebaum, B
Rabe, T
Köhn, FM
机构
[1] Heidelberg Univ, Dept Obstet & Gynaecol, Div Gynaecol Endocrinol & Reprod, D-69115 Heidelberg, Germany
[2] Univ Giessen, Dept Dermatol, Giessen, Germany
关键词
human mammary carcinoma cell line MCF-7; leukotrienes; arachidonate; lipoxygenase; cell growth;
D O I
10.1016/S0301-2115(97)00217-0
中图分类号
R71 [妇产科学];
学科分类号
100211 ;
摘要
Objectives: The aim of this work was to study the action of leukotrienes on the growth of human mammary cancer cells MCF-7. Study design: The growth of the cells was measured by incorporation of H-3-thymidine. The action of leukotriene (LT)B4, LTD4, LTC4, LTE4 or arachidonate (AA) was tested in human mammary cancer cells MCF-7 in vitro. Results: LTB4 or LTD4 but not LTC4 or LTE4 reduced significant incorporation of H-3-thymidine in MCF-7 cells up to 52% or 56% respectively, when administered in concentrations 0.1-1000 pM. Agents in concentrations of 0.01 pM or 10 000 pM did not effect 3H-thymidine incorporation. We have shown, that MCF-7 cells synthesise LTB4 when treated with calcium ionophor A23187 (10 mu M). Leukotriene-antagonist LY171883 (10 mu M) lifts inhibitory effects of LTB4 or LTD4. Arachidonic acid (10 mu M) inhibits 3H-thymidine incorporation up to 72%. 5-lipoxygenase inhibitor MK-886 (100 nM) lifts the inhibitory effect of arachidonate. Conclusions: LTB4 or LTD4 inhibits MCF-7 breast cancer cell growth. LT-receptors mediate the growth-inhibitory effect of LTB4 or LTD4. (C) 1998 Elsevier Science Ireland Ltd.
引用
收藏
页码:61 / 65
页数:5
相关论文
共 50 条
  • [41] Methionine cytotoxicity in the human breast cancer cell line MCF-7
    Hyung H. Kim
    Chung S. Park
    In Vitro Cellular & Developmental Biology - Animal, 2003, 39 : 117 - 119
  • [42] Methionine cytotoxicity in the human breast cancer cell line MCF-7
    Kim, HH
    Park, CS
    IN VITRO CELLULAR & DEVELOPMENTAL BIOLOGY-ANIMAL, 2003, 39 (3-4) : 117 - 119
  • [43] Weightlessness acts on human breast cancer cell line MCF-7
    Vassy, J
    Portet, S
    Beil, M
    Millet, G
    Fauvel-Lafève, F
    Gasset, G
    Schoevaert, D
    SPACE LIFE SCIENCES: GRAVITATIONAL BIOLOGY: 2002, 2003, 32 (08): : 1595 - 1603
  • [44] In vitro antibreast cancer efficacy of two indigenous plants on human cancer cell line MCF-7
    Ojeswi, B. K.
    Khoobchandani, M.
    Arora, J. K.
    Hazra, D. K.
    Srivastava, M. M.
    NATIONAL ACADEMY SCIENCE LETTERS-INDIA, 2009, 32 (3-4): : 105 - 109
  • [45] Electromagnetic field as an environmental factor affecting MCF-7 cell line in vitro
    Koziorowska, Anna
    Koziol, Katarzyna
    Hajduga, Ewelina
    Romerowicz-Misielak, Maria
    PRZEGLAD ELEKTROTECHNICZNY, 2019, 95 (05): : 5 - 8
  • [46] Steroid metabolism in the hormone dependent MCF-7 human breast carcinoma cell line and its two hormone resistant subpopulations MCF-7/LCC1 and MCF-7/LCC2
    Jorgensen, L
    Brünner, N
    Spang-Thomsen, M
    James, MR
    Clarke, R
    Dombernowsky, P
    Svenstrup, B
    JOURNAL OF STEROID BIOCHEMISTRY AND MOLECULAR BIOLOGY, 1997, 63 (4-6): : 275 - 281
  • [47] A FACTOR FROM PLASMA-DERIVED HUMAN-SERUM THAT INHIBITS THE GROWTH OF THE MAMMARY CELL-LINE MCF-7 - CHARACTERIZATION AND PURIFICATION
    DELLAQUILA, ML
    PIGOTT, DA
    BONAQUIST, DL
    GAFFNEY, EV
    JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 1984, 72 (02): : 291 - 298
  • [48] EFFECTS OF BETA TRANSFORMING GROWTH-FACTOR ON HUMAN MAMMARY ADENOCARCINOMA CELL-LINES (MCF-7)
    VALETTE, A
    BOTANCH, C
    GUILBAUD, N
    BULLETIN DU CANCER, 1988, 75 (07) : 694 - 695
  • [49] ANTAGONISM OF CYCLOFENIL AND NAFOXIDINE IN THE GROWTH OF THE HUMAN-BREAST CANCER CELL-LINE MCF-7
    DEVLEESCHOUWER, N
    LECLERCQ, G
    HEUSON, JC
    IRCS MEDICAL SCIENCE-BIOCHEMISTRY, 1980, 8 (11): : 849 - 849
  • [50] POLYAMINE REQUIREMENT FOR PROLACTIN ACTION ON MACROMOLECULAR-SYNTHESIS IN THE MCF-7 HUMAN MAMMARY EPITHELIAL-CELL LINE
    LINEBAUGH, BE
    RILLEMA, JA
    BIOCHIMICA ET BIOPHYSICA ACTA, 1984, 804 (03) : 348 - 355